Short Interest in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Decreases By 31.0%

Key Points

• Short interest in Xtant Medical Holdings, Inc. decreased by 31.0% in September, dropping from 62,200 shares to 42,900 shares.
• Xtant Medical's stock is currently trading at $0.77, reflecting a 1.4% decline, with a market capitalization of $107.90 million.
• Institutional investors have significantly increased their positions in Xtant Medical, with Nantahala Capital Management raising its holdings by 500.3% during the second quarter.

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - ) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 42,900 shares, a decrease of 31.0% from the September 15th total of 62,200 shares. Based on an average daily volume of 90,300 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily volume of 90,300 shares, the days-to-cover ratio is presently 0.5 days.

Xtant Medical Stock Down 1.4%

Shares of XTNT stock traded down $0.01 on Thursday, hitting $0.77. The stock had a trading volume of 127,314 shares, compared to its average volume of 134,391. The firm has a market capitalization of $107.90 million, a price-to-earnings ratio of -19.27 and a beta of -0.22. The stock's 50 day moving average is $0.66 and its 200-day moving average is $0.61. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.16 and a current ratio of 2.47. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $0.84.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in XTNT. Nantahala Capital Management LLC raised its holdings in Xtant Medical by 500.3% in the second quarter. Nantahala Capital Management LLC now owns 68,394,000 shares of the medical device company's stock valued at $50,543,000 after acquiring an additional 57,000,000 shares in the last quarter. Mink Brook Asset Management LLC grew its position in Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company's stock valued at $81,000 after buying an additional 60,997 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Xtant Medical during the 2nd quarter valued at about $26,000. AWM Investment Company Inc. bought a new position in shares of Xtant Medical during the 2nd quarter valued at about $4,875,000. Finally, Crescent Grove Advisors LLC lifted its stake in Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company's stock valued at $304,000 after buying an additional 200,000 shares in the last quarter. 69.33% of the stock is currently owned by hedge funds and other institutional investors.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.